Ascentage Pharma Group

Ascentage Pharma is an integrated global biopharmaceutical company engaged in discovering, developing and commercializing both first- and best-in-class cancer therapies. Learn more on ClinicalTrials.gov.

We are a commercial stage biopharmaceutical company with a global footprint. We have fully integrated capabilities from discovery, clinical development to manufacturing and commercialization. We adopt a global clinical development strategy and leverage our CMC (chemistry, manufacturing, and controls) to comply with the requirements applicable to clinical trials globally in accordance with the requirements of Read More ›

SUZHOU, China, and ROCKVILLE, MD., Jan. 11, 2022 — Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that Dr. Dajun Yang, the company’s Chairman and CEO, delivered a presentation at the virtually-held 40th Annual J.P. Morgan Healthcare Conference in the Read More ›

ROCKVILLE, MD and HONG KONG, CHINA | Ascentage Pharma, a global clinical stage biopharmaceutical company dedicated to developing apoptosis-targeted therapies for cancers and other diseases, today announced that the China Food and Drug Administration (CFDA) has accepted the Investigational New Drug (IND) application for APG-1387, a novel small molecule IAP inhibitor for the treatment of the Hepatitis B virus (HBV) infection. APG-1387 is the Read More ›

ROCKVILLE, MD and HONG KONG, CHINA /PRNewswire/ - Ascentage Pharma, a global clinical-stage biopharmaceutical company dedicated to developing apoptosis-targeted therapies for cancers and other diseases, today announced that research on its pipeline of small molecule therapeutics will be presented at the 2018 American Association for Cancer Research (AACR) annual meeting in Chicago, April 14-18, 2018. “The Read More ›

ROCKVILLE, Md. and HONG KONG /PRNewswire/ - Ascentage Pharma, a global clinical-stage biopharmaceutical company dedicated to developing apoptosis-targeted therapies for cancers and other diseases, today announced the formation of a Clinical Advisory Board (CAB) to provide strategic guidance to the Company as it advances its pipeline of novel, apoptosis-targeted therapies and next-generation tyrosine kinase inhibitors. The newly formed board Read More ›

ROCKVILLE, MARYLAND | Ascentage Pharma, a global clinical-stage biopharmaceutical company dedicated to developing apoptosis-targeted therapies, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for APG-1387, a novel small molecule IAP inhibitor for the treatment of advanced solid tumors and hematologic malignancies. Inhibitors of apoptosis (IAPs) Read More ›

Main Responsibilities: Provide Pharmacovigilance (PV) support for patient safety risk management in clinical studies and life cycle management of responsible company product(s) Partner with cross functional teams for safety reporting Maintain current knowledge and understanding of regulations, ICH guidelines and industry practices in relation to pharmacovigilance (PV) Keep abreast of new or changes in local Read More ›

We are a global, integrated biopharmaceutical company engaged in discovering, developing and commercializing both first- and best-in-class therapies to address global unmet medical needs primarily in hematological malignancies. Our lead assets, olverembatinib and lisaftoclax, have global potential to address the major hematological malignancies, including chronic myeloid leukemia, or CML, acute myeloid leukemia, or AML, chronic Read More ›

Ascentage Pharma is an integrated global biopharmaceutical company engaged in discovering, developing and commercializing both first- and best-in-class therapies to address global unmet medical needs. For more than two decades, our founders and team have leveraged their deep expertise to develop our proprietary drug discovery platform to pursue particularly challenging targets. We are the only Read More ›

TERMS OF USE Effective: September 24, 2018 Acceptance of the Terms and Conditions. 1.1 Ascentage Pharma Group International (herein referred to as the “Ascentage,” “we,” “us” or “our”) provides and makes available this website (the “Site”). This Site is operated by Ascentage and has been created to provide to our Site visitors (“you,” “your”) information about Read More ›

Ascentage Pharma reports **29% year-over-year revenue growth** in the first half of 2026, reaching **US$44.5 million (RMB 302.2 million)** driven by increased product sales. The company expands leadership with **Dr. Faical Miyara as Chief Business Officer** and **Mr. James Ziegler as Chief Commercial Officer**. Nine **Phase III clinical trials** are ongoing globally, with four approved by regulatory authorities.

Aug 2026ascentage.comNews article

Ascentage Pharma presents clinical study results for **olverembatinib**, including the first dataset from the **POLARIS-1 trial**, at the **ASH 2025** conference. The company focuses on developing novel cancer therapies, with olverembatinib targeting unmet medical needs in oncology. Data from multiple studies will be shared, highlighting progress in its late-stage pipeline.

Nov 2025ascentage.comNews article

Ascentage Pharma releases its **2025 interim unaudited financial results for the first six months**, detailing performance as a commercial-stage biopharmaceutical company focused on cancer therapies. The company highlights progress in its **novel therapy pipeline**, targeting unmet medical needs in oncology. Updates include operational and business developments, though specific figures or milestones are not disclosed in the excerpt.

Aug 2025BioSpaceNews article

Ascentage Pharma completes its U.S. IPO with a $126.2 million raise by selling 7.3 million American depositary shares at $17.25 each. The biotech firm, listed on Nasdaq as **AAPG** and HKEX as **6855**, secures capital through the offering before underwriting fees. Each ADS corresponds to four ordinary shares of the company.

Jan 2025ascentage.comNews article